David Howat, an experienced pharma research and development manager, has joined Ribonexus SAS of France as chief development officer (CDO). Ribonexus is developing a pipeline of drugs targeting a protein which is associated with a cancer’s resistance to many current therapies. Dr Howat was previously CDO at Haoma Medica Ltd, a UK biotech, and CDO and head of R&D at Evgen Pharma Plc in the UK.
Ribonexus announced the appointment on 9 May 2023.
Copyright 2023 Evernow Publishing Ltd